Biopharmaceutical company Amarin announced top-line results for its purified eicosapentaenoic acid (EPA) product in September, hailing the 25 percent risk reduction in a composite of cardiovascular outcomes associated with icosapent ethyl (Vascepa). But critics who commented on the results to Kaiser Health News worried the excitement over the trial is premature.

Following President Trump’s recent comments about rescinding birthright citizenship in the U.S., one pediatric cardiologist is speaking out about his own history and career at Vanderbilt—a career, he says, that wouldn’t be possible without the 14th amendment.

A London, Kentucky, cardiologist was sentenced to 42 months in federal prison Oct. 31 after reportedly implanting “dozens” of unnecessary pacemakers and defrauding both his patients and their insurers, U.S. Attorney Robert M. Duncan, Jr., has announced.

The British government has released a new return on investment (ROI) tool to help guide local commissioners in preventing cardiovascular disease and cutting healthcare costs in their communities, Public Health England (PHE) announced last week.

The relative value unit (RVU)-based compensation model in U.S. academic medical centers can twist incentives and prioritize clinical productivity over research and teaching, three researchers argued in a viewpoint published Oct. 20 in the European Heart Journal.

Amgen is slashing the list price of its PCSK9 inhibitor evolocumab (Repatha) by almost 60 percent, the company announced Oct. 24.

Rates of malpractice lawsuits in cardiology have followed a slow upward trajectory for the past decade and are continuing to climb, according to a review of more than 1,500 liability claims published in the American Journal of Cardiology.

The FDA rejected Norvartis’ bid to expand the indications for canakinumab to include cardiovascular risk reduction among heart attack survivors, Reuters reported Oct. 18.